W. Lasek

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
W A Lasek, W Lasek, W. Lasek, Witold Lasek
Publication record
98 papers · 3,809 citations · H-index 21

PAPERS

Cancer immunoediting hypothesis: history, clinical implications and controversies
202230 citationsauthor #1
Therapeutic metastatic prostate cancer vaccines: lessons learnt from urologic oncology
202115 citationsauthor #1
Comparative Study of Immunomodulatory Agents to Induce Human T Regulatory (Treg) Cells: Preferential Treg-Stimulatory Effect of Prednisolone and Rapamycin
202018 citationsauthor #6
Comparative Study of Immunomodulatory Agents to Induce Human T Regulatory (Treg) Cells: Preferential Treg-Stimulatory Effect of Prednisolone and Rapamycin
20200 citationsauthor #6
Synergistic antitumor effects of histone deacetylase inhibitor scriptaid and bortezomib against ovarian cancer cells.
20189 citationsauthor #4
Potentialization of N-a-tosyl-L-phenylalanine chloromethyl ketone (TPCK) cytotoxic activity by 2-(1-adamantylamino)-6-methylpyridine (AdAMP) in human ovarian cancer cells.
20170 citationsauthor #2
Inhibition of adenovirus multiplication by inosine pranobex and interferon α in vitro
201611 citationsauthor #2
Antitumor Effects of IL-12 in Preclinical Studies
20160 citationsauthor #1
DRUG BIOCHEMISTRY IN VITRO INHIBITION OF HHV-1 REPLICATION BY INOSINE PRANOBEX AND INTERFERON-α
20161 citationsauthor #2
Biology of IL-12
20164 citationsauthor #2
Interleukin 12: Antitumor Activity and Immunotherapeutic Potential in Oncology
20168 citationsauthor #1
Inhibitory Effect of Alloferons in Combination with Human Lymphocytes on Human Herpesvirus 1 (HHV-1) Replication In Vitro
20163 citationsauthor #2
Interferon-α and inosine pranobex-mediated inhibition of reploication of human RNA viruses in vitro.
20161 citationsauthor #2
Clinical Trials with IL-12 in Cancer Immunotherapy
20165 citationsauthor #1
IN VITRO INfIBITION OF HHV-1 REPLICATION BY INOSINE PRANOBEX AND INTERFERON-α.
20167 citationsauthor #2
Inhibitory Effect of Alloferons in Combination with Human Lymphocytes on Human Herpesvirus 1 (HHV-1) Replication In Vitro
20150 citationsauthor #2
[Inosine pranobex - cytotoxic activities and effect of on replication of human parainfluenza viruses (HPIV-2, HPIV-4), entroviruses (CA16, EV71) and adenoviruses (HAdV-2, HAdV-5) in vitro].
20154 citationsauthor #2
Immunomodulatory effects of inosine pranobex on cytokine production by human lymphocytes
201546 citationsauthor #1
Interleukin 12: still a promising candidate for tumor immunotherapy?
2014425 citationsauthor #1
From immunology to modeling, processing and analysis of data
20130 citationsauthor #2
Synergistic antitumor effect of JAWSII dendritic cells and interleukin 12 in a melanoma mouse model.
20139 citationsauthor #5
Synergistic cytotoxic effect of sulindac and pyrrolidine dithiocarbamate against ovarian cancer cells
20125 citationsauthor #5
Optimization of activation requirements of immature mouse dendritic JAWSII cells for in vivo application.
201115 citationsauthor #6
Interleukin 15 as a promising candidate for tumor immunotherapy.
2011130 citationsauthor #3
[Antitumor effects of sulindac in ovarian cell cultures].
20116 citationsauthor #5
Decreased antibody-dependent cellular cytotoxicity in various types of leukaemia in man.
20097 citationsauthor #7
Statins Impair Antitumor Effects of Rituximab by Inducing Conformational Changes of CD20
20081,947 citationsauthor #17
Interleukin 15 augments antitumor activity of cytokine gene-modified melanoma cell vaccines in a murine model.
200828 citationsauthor #6
Statins Impair Antitumor Effects of CD20 mAb by Inducing Conformational Changes of CD20.
20070 citationsauthor #15
TNF-α Production-enhancing Activity of 2-(1-Adamantylamino)-6-methylpyridine (AdAMP) in Cultures of Human Normal and Neoplastic Cells
20063 citationsauthor #2
TNF-alpha production-enhancing activity of 2-(1-adamantylamino)-6-methylpyridine (AdAMP) in cultures of human normal and neoplastic cells.
20060 citationsauthor #2
Modes of Securing Information Systems
20060 citationsauthor #2
Tumor Necrosis Factor-α Production-Enhancing Properties of Novel Adamantylalkylthio Derivatives of Some Heterocyclic Compounds
20051 citationsauthor #4
Technology evaluation: HYB-2055, Hybridon.
20055 citationsauthor #2
CpG Immunostimulatory Oligodeoxynucleotide 1826 Enhances Antitumor Effect of Interleukin 12 Gene-Modified Tumor Vaccine in a Melanoma Model in Mice
200436 citationsauthor #14
Adamantylsulfanyl‐ and N‐Adamantylcarboxamido‐Derivatives of Heterocycles and Phenoles: Synthesis, Crystal Structure, Tumor Necrosis Factor‐α Production‐Enhancing Properties, and Theoretical Considerations
200410 citationsauthor #2
Complete tumour regressions induced by vaccination with IL-12 gene-transduced tumour cells in combination with IL-15 in a melanoma model in mice
200449 citationsauthor #1
Natural mechanisms protecting against cancer.
2003208 citationsauthor #2
Tumor necrosis factor-alpha production-regulating activity of phthalimide derivatives in genetically modified murine melanoma cells B78H1.
200311 citationsauthor #2
Tumor Necrosis Factor‐Alpha Production‐Regulating Activity of Phthalimide Derivatives in Genetically Modified Murine Melanoma Cells B78H1.
20031 citationsauthor #2
Interleukin 12-based immunotherapy improves the antitumor effectiveness of a low-dose 5-Aza-2'-deoxycitidine treatment in L1210 leukemia and B16F10 melanoma models in mice.
200353 citationsauthor #8
Lovastatin potentiates antitumor activity of doxorubicin in murine melanoma via an apoptosis‐dependent mechanism
200292 citationsauthor #6
A search for new tumor necrosis factor-α secretion enhancement agents
20020 citationsauthor #5
IL-12 or IL-15, unlike IL-2, does not interact with histamine in augmenting cytotoxicity of splenocytes against melanoma cells and YAC-1 cells.
20024 citationsauthor #8
Synthesis and biological properties of S-adamantylated heterocyclic compounds.
20020 citationsauthor #4
Stimulation of TNF-α production by 2-(1-adamantylamino)-6-methylpyridine (AdAMP) – a novel immunomodulator with potential application in tumour immunotherapy
20024 citationsauthor #1
Synthesis, structure and tumour necrosis factor-alpha production-enhancing properties of novel adamantylamino heterocyclic derivatives.
20016 citationsauthor #2
Butyric acid enhances in vivo expression of hTNF-α in transduced melanoma cell line
20013 citationsauthor #7
Potentiatied antitumor effectiveness of combined chemo-immunotherapy with Interleukin-12 and 5-fluorouracil of L1210 leukemia in vivo
200123 citationsauthor #10
Butyric acid enhances in vivo expression of hTNF-alpha in transduced melanoma cell line.
20013 citationsauthor #7
Adamantylaminopyrimidines and -pyridines are potent inducers of tumor necrosis factor-alpha.
200121 citationsauthor #4
Adamantylaminopyrimidines and -pyridines Are Potent Inducers of Tumor Necrosis Factor-α.
20013 citationsauthor #4
Antitumor effects of the combination therapy with TNF-α gene–modified tumor cells and interleukin 12 in a melanoma model in mice
200032 citationsauthor #1
Interleukin 12 and indomethacin exert a synergistic, angiogenesis-dependent antitumor activity in mice.
200014 citationsauthor #9
Potentiation of the anti-tumour effects of Photofrin®-based photodynamic therapy by localized treatment with G-CSF
200057 citationsauthor #14
Potentiatied anti-tumor effectiveness of combined therapy with interleukin-12 and mitoxantrone of L1210 leukemia in vivo.
200015 citationsauthor #7
[Cytokines as therapeutics--application in oncology].
19990 citationsauthor #1
Subtherapeutic doses of interleukin-15 augment the antitumor effect of interleukin-12 in a B16F10 melanoma model in mice.
199933 citationsauthor #1
Effective chemo‐immunotherapy of L1210 leukemia in vivo using interleukin‐12 combined with doxorubicin but not with cyclophosphamide, paclitaxel or cisplatin
199841 citationsauthor #7
Granulocyte-Macrophage Colony-Stimulating Factor Potentiates Antitumor Activity of Interleukin-12 in Melanoma Model in Mice
19987 citationsauthor #12
G-CSF prevents the suppression of bone marrow hematopoiesis induced by IL-12 and augments its antitumor activity in a melanoma model in mice.
199833 citationsauthor #10
Antitumor effects of the combination immunotherapy with interleukin-12 and tumor nectosis factor α in mice
19970 citationsauthor #1
Augmented antitumor effects of combination therapy with interleukin-12, cisplatin, and tumor necrosis factor-alpha in a murine melanoma model.
199721 citationsauthor #6
Antitumor effects of the combination immunotherapy with interleukin-12 and tumor necrosis factor α in mice
199771 citationsauthor #1
Antitumor effects of the combination immunotherapy with interleukin-12 and tumor nectosis factor-α in mice
19970 citationsauthor #1
Granulocyte-macrophage colony-stimulating factor accelerates growth of Lewis lung carcinoma in mice.
19969 citationsauthor #4
Potentiation of the anti‐tumor effect of actinomycin D by tumor necrosis factor α in mice: Correlation between in vitro and in vivo results
199632 citationsauthor #1
Augmented antitumor effect of tumor necrosis factor-α used together with interferon-γ and lovastatin against MmB16 melanoma in mice
19960 citationsauthor #5
Augmentation of antitumor efficacy by the combination of actinomycin D with tumor necrosis factor-alpha and interferon-gamma on a melanoma model in mice.
199610 citationsauthor #1
Synergistic antitumor activity of tumor necrosis factor-alpha and lovastatin against MmB16 melanoma in mice.
199519 citationsauthor #2
Potentiation of antitumor effects of tumor necrosis factor α and interferon γ by macrophage-colony-stimulating factor in a MmB16 melanoma model in mice
199522 citationsauthor #1
Combination of immunotherapy with cyclophosphamide/actinomycin D chemotherapy potentiates antileukemic effect and reduces toxicity in a L1210 leukemia model in mice.
199510 citationsauthor #1
Potentiation of antitumor effects of tumor necrosis factor alpha and interferon gamma by macrophage-colony-stimulating factor in a MmB16 melanoma model in mice.
19958 citationsauthor #1
Synergistic antiproliferative activity of tumor necrosis factor alpha (TNF-alpha) and lovastatin.
199418 citationsauthor #5
Decreased natural killer cell activity in whole‐blood donors does not seem to result in increased cancer incidence
199413 citationsauthor #1
Effect of blood transfusion and cyclophosphamide on cardiac allograft survival in sensitized mice.
19940 citationsauthor #1
Two patterns of NK activity changes following blood donation: decrease in the beginners and restoration in regular blood bank donors.
19926 citationsauthor #1
Application of Rule Induction Algorithm in Medical Research
19910 citationsauthor #2
Local administration of cyclosporin allows reduction of the dose prolonging survival of heart tissue allografts.
19900 citationsauthor #4
An in vitro test for immunomodulators?
19905 citationsauthor #2
6.11 In vivo factors affecting NK cell activity in the normal human population
19890 citationsauthor #1
Opposite effect of donor-specific immunization by blood or splenocytes on the survival of heart tissue transplants in strong versus weak histoincompatible combination in mice.
19890 citationsauthor #1
The influence of pretransplant and posttransplant immunosuppression on cardiac graft survival in the donor-specific transfusion model in mice. Comparison of the effects of cyclophosphamide, procarbazine, cyclosporine, and cortisone.
19899 citationsauthor #1
The stimulation of EL-4 cells to produce interleukin-2 and its potential use in immunocytotoxicity testing.
19897 citationsauthor #1
The influence of ABO blood groups, Rh antigens and cigarette smoking on the level of NK activity in normal population.
19892 citationsauthor #1
The influence of blood donation on antibody-dependent cellular cytotoxicity (ADCC) in voluntary blood bank donors.
19883 citationsauthor #1
The influence of blood withdrawal on NK activity in mice.
19881 citationsauthor #1
The role of drug timing and histoincompatibility barrier in prolongation of cardiac graft survival in mice treated with donor-specific blood and cyclophosphamide.
19886 citationsauthor #1
The effect of blood donation on natural killer activity in man.
198721 citationsauthor #1
Relationship between natural killer (NK) activity and eosinophil, neutrophil and lymphocyte level in human blood.
19854 citationsauthor #1
Transfusions of syngeneic blood do not seem to induce suppressive effect on antitumor or transplantation immunity in mice.
19856 citationsauthor #3
Specific and non-specific immunotherapy of Ehrlich Ascites Carcinoma in mice.
19821 citationsauthor #3
Augmentation of in vivo antitumour activity of xenogeneic antiserum by autotransplanted normal spleen cells in mice.
19811 citationsauthor #3
Augmentation of antitumour activity of xenogeneic antiserum by normal xenogeneic spleen cells in mice.
19810 citationsauthor #2
Influence of immunosuppressive pretreatment on the survival of mice challenged with Ehrlich ascites carcinoma (EAC).
19800 citationsauthor #2
ANALYSIS OF CRYSTAL PACKING EFFECTS USING RELIBASE+
year unknown0 citationsauthor #5
Kazimierczuk Stimulation of TNF-a production by 2-( 1-adamantylamino )-6-methylpyridine ( AdAMP ) – a novel immunomodulator with potential application in tumour immunotherapy
year unknown0 citationsauthor #1
ROLE OF INTERLEUKIN 15 IN PATHOGENESIS AND THERAPY OF HUMAN DISEASES
year unknown0 citationsauthor #6

TIMELINE

1980 0 citations

1981 1 citations

1982 1 citations

1985 10 citations

1987 21 citations

1988 10 citations

1989 18 citations

1990 5 citations

1991 0 citations

1992 6 citations

1994 31 citations

1995 59 citations

1996 51 citations

1997 92 citations

1998 81 citations

1999 33 citations

2000 118 citations

2001 59 citations

2002 100 citations

2003 273 citations

2004 95 citations

2005 6 citations

2006 3 citations

2007 0 citations

2008 1,975 citations

2009 7 citations

2011 151 citations

2012 5 citations

2013 9 citations

2014 425 citations

2015 50 citations

2016 40 citations

2017 0 citations

2018 9 citations

2020 18 citations

2021 15 citations

2022 30 citations

Unknown 0 citations

COAUTHOR MAP

CONCEPT FOOTPRINT